dc.contributor.author | Sen, S. | |
dc.contributor.author | Tuncer, A. | |
dc.contributor.author | Ozakbas, S. | |
dc.contributor.author | Uzunkopru, C. | |
dc.contributor.author | Baba, C. | |
dc.contributor.author | Demir, S. | |
dc.contributor.author | Beckmann, Y. | |
dc.contributor.author | Gumus, H. | |
dc.contributor.author | Arslan, G. | |
dc.contributor.author | Kilic, A.K. | |
dc.contributor.author | Altintas, A. | |
dc.contributor.author | Yuceyar, N. | |
dc.contributor.author | Turan, O.F. | |
dc.contributor.author | Tutuncu, M. | |
dc.contributor.author | Terzi, M. | |
dc.contributor.author | Acar, P. | |
dc.contributor.author | Bunul, S.D. | |
dc.contributor.author | Balci, B.P. | |
dc.contributor.author | Bir, L.S. | |
dc.contributor.author | Koseoglu, M. | |
dc.contributor.author | Mungan, S. | |
dc.contributor.author | Gunduz, T. | |
dc.contributor.author | Dogan, I.G. | |
dc.contributor.author | Kotan, D. | |
dc.contributor.author | Uygunoglu, U. | |
dc.contributor.author | Ekmekci, O. | |
dc.contributor.author | Demirkiran, M. | |
dc.contributor.author | Kamisli, O. | |
dc.contributor.author | Kabay, S.C. | |
dc.contributor.author | Tamam, Y. | |
dc.contributor.author | Omerhoca, S. | |
dc.contributor.author | Sevim, S. | |
dc.contributor.author | Guler, S. | |
dc.contributor.author | Kurtuncu, M. | |
dc.contributor.author | Efendi, H. | |
dc.contributor.author | Karabudak, R. | |
dc.contributor.author | Siva, A. | |
dc.date.accessioned | 2022-10-06T12:54:36Z | |
dc.date.available | 2022-10-06T12:54:36Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 22110348 (ISSN) | |
dc.identifier.uri | http://hdl.handle.net/11616/72333 | |
dc.description.abstract | Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection. © 2021 Elsevier B.V. | |
dc.source | Multiple Sclerosis and Related Disorders | |
dc.title | The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course? |
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |